Apr 30, 2024, 12:22
Harold Burstein: ER-low tumors will require chemotherapy and endocrine therapy
Harold Burstein, Breast Cancer Specialist and Professor at Dana Farber Cancer Institute, shared a post by Annals of Surgical Oncology on X/Twitter, adding:
”Key clinical takeaway is that in contemporary breast cancer pathology, most ER-low (< 10%) tumors will require chemotherapy and endocrine therapy.”
Quoting Annals of Surgical Oncology’s post:
”April Issue: Defining the Biology of Estrogen Receptor-Low-Positive.”
Source: Harold Burstein/X and AnnalsSurgOncology/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 23, 2024, 16:25
Oct 23, 2024, 16:03
Oct 23, 2024, 15:44
Oct 23, 2024, 15:44
Oct 23, 2024, 15:42
Oct 23, 2024, 15:15